$REPH Recro Pharma, Inc. Insider Trading
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Recro Pharma, Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in Recro Pharma, Inc. for free.
CIK Number: 0001588972
IRS Number: 261523233
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: REPH
Company Address: 1 E. UWCHLAN AVE, SUITE 112 EXTON 19341
Phone number: (484) 395-2400
Market Capitalization: $98.40M
Prev close: $8.05
Average Daily Volume: 252,423
Days Low: $8.06
Year Low: $5.59
Year High: $12.50
Recro Pharma, Inc. Latest Insider Transactions
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Grant | A | 0.00 | 26,923 | 0 | 26,923 | 0 to 26.9 K |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 26,923 | 0 | 84,982 | 58.1 K to 85 K (+46.37 %) |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 26,923 | 0 | 67,429 | 40.5 K to 67.4 K (+66.47 %) |
Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Grant | A | 0.00 | 26,923 | 0 | 226,574 | 199.7 K to 226.6 K (+13.49 %) |
Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 26,923 | 0 | 77,982 | 51.1 K to 78 K (+52.73 %) |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 26,923 | 0 | 76,546 | 49.6 K to 76.5 K (+54.26 %) |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 26,923 | 0 | 80,280 | 53.4 K to 80.3 K (+50.46 %) |
Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 |